{"id":48490,"date":"2025-07-30T21:35:16","date_gmt":"2025-07-30T21:35:16","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/48490\/"},"modified":"2025-07-30T21:35:16","modified_gmt":"2025-07-30T21:35:16","slug":"cell-gene-therapy-contract-research-organizations-market-size-to-surpass-usd-13-76-billion-by-2034","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/48490\/","title":{"rendered":"Cell & Gene Therapy Contract Research Organizations Market Size to Surpass USD 13.76 Billion by 2034"},"content":{"rendered":"

<\/p>\n

According to Nova One Advisor, the global cell
\n& gene therapy contract research organizations market size<\/a> is
\ncalculated at USD 5.35 billion in 2024, grows to USD 5.88 billion in 2025, and
\nis projected to reach around USD 13.76 billion by 2034, growing at a CAGR of
\n9.91% from 2025 to 2034.<\/p>\n

<\/p>\n

The cell & gene therapy contract
\nresearch organizations market is expanding due to CRO<\/a>
\noffering numerous advantages for cell
\nand gene therapy<\/a>, such as speed, expertise, and flexibility. CRO is
\nthat it authorizes sponsors to make informed decisions, keep trial quality, use
\nresources effectively, and reduce interruptions. It offers auditable financials
\nand improves resource allocation to lower operational expenses of cell and gene
\ntherapies.<\/p>\n

The Complete Study is Now Available for
\nImmediate Access | Download the Sample Pages of this Report@ https:\/\/www.novaoneadvisor.com\/report\/sample\/9185<\/a>\n<\/p>\n

Cell & Gene Therapy Contract
\nResearch Organizations Market Highlights:<\/p>\n

\u2022 North America dominated the global bone
\nregeneration material market in 2024.<\/p>\n

\u2022 Asia Pacific is expected to grow at the
\nfastest CAGR over the forecast period.<\/p>\n

\u2022 By type, the clinical segment dominated
\nthe market with the largest share in 2024.<\/p>\n

\u2022 By type, the preclinical segment is
\nexpected to show the fastest growth over the forecast period.<\/p>\n

\u2022 By service, the clinical monitoring
\nsegment accounted for the highest market share in 2024.<\/p>\n

\u2022 By service, the regulatory strategy
\nsegment is expected to expand rapidly during the predicted timeframe.<\/p>\n

\u2022 By indication, the oncology segment held
\nthe largest market share in 2024.<\/p>\n

\u2022 By indication, the CNS disorders segment
\nis expected to register the fastest growth during the forecast period.<\/p>\n

\u2022 By modality, the cell-based therapies
\nsegment captured the largest market share in 2024.<\/p>\n

\u2022 By modality, the gene therapies segment
\nis expected to show the fastest growth during the forecast period.<\/p>\n

Market Overview and Industry Potential<\/p>\n

The cell and gene therapy contract research
\norganizations market is expanding due to CROs bringing valuable resources and
\nabilities to the cell and gene therapies, which accelerates timelines and
\nefficient processes through government expertise and access to advanced technologies.
\nCROs have a deep understanding of the governing landscape and can navigate the
\ncomplex maze of regulations and guidelines that govern cell and gene
\ntherapy<\/a> research. They have dedicated teams of specialists who stay up
\nto date with the modern regulatory changes and ensure that the study remains
\ncompliant throughout its period. This level of government expertise helps avoid
\ncostly delays and ensures that research progresses efficiently.<\/p>\n

\u2b25\ufe0e For Instance, In September 2024, Cryoport, Inc<\/a>., a global leader in
\nsupply chain solutions for the life sciences industry, and SK pharmteco, a
\nworldwide contract development and manufacturing organization, announced a
\nstrategic collaboration to provide fully integrated logistics and manufacturing
\nservices to biotechnology and pharmaceutical companies.<\/p>\n

Continuous increasing interest in cell and
\ngene therapy outsourcing provides access to a specialised organization\u2019s
\ninternal resources, including its equipment and in-house specialists. Working
\nwith a proficient CRO, customers usually scale up faster with their services.
\nCRO continuously examine and progress their portfolios and what they can offer
\nto their novel cell
\nand gene therapy customers<\/a>.\u00a0 <\/p>\n

CRO to handle entirely aspects of a clinical
\ntrial<\/a> or advancement program, fundamentally end-to-end. The CRO is
\nresponsible for the complete study operations, and the sponsor\u2019s contribution
\nis primarily oversight and decision-making.<\/p>\n

What are the Latest Trends of Cell &
\nGene Therapy Contract Research Organizations Market?<\/p>\n

\u2b25\ufe0e In July 2025, the Centers for Medicare
\n& Medicaid Services (CMS) announced that 33 states, plus the District of
\nColumbia and Puerto Rico, will participate in the Cell and Gene Therapy (CGT)
\nAccess Model, a bold novel strategy to delivering advanced treatments for
\npeople on Medicaid living with sickle cell disease. Participating states
\nrepresent approximately 84% of Medicaid beneficiaries with the condition,
\nsignificantly expanding access to transformative care.<\/p>\n

\u2b25\ufe0e In April 2025, Charles River Laboratories International, Inc<\/a>.
\nannounced the initial cohort of its Charles River Incubator Program (CIP). The
\nprogram offers early-stage biotechnology pioneers access to extensive scientific
\nand commercial expertise and a wide ecosystem of discovery, development, and
\nmanufacturing capabilities to expedite the development of technologies and
\nlife-changing therapies for patients in need.<\/p>\n

Increasing Demand for Personalized Cell
\nTherapies: Market\u2019s Largest Potential<\/p>\n

Growing demand for personalize cell
\ntherapies as it provides major advantages, ranging from enhancing diagnostic
\nprecision to recognizing the ideal treatment option for a patient based on
\ntheir characteristics, to targeted therapy that rises the likelihood of
\neffective treatments, lowers adverse effects, enables for better disease
\nprevention, and most significantly, increases patient engagement, lowers
\nmedical care expenses, and promotes research and revolution, so these create strong
\ndemand of scalable, flexible and rapid advancement platforms, CROs are
\nparticularly good at providing.<\/p>\n

\u2b25\ufe0e For Instance, In February 2024,
\nAstraZeneca expands its US manufacturing footprint to accelerate ambitions in
\nnext-generation cell therapy discovery and development. AstraZeneca is
\ninvesting $300 million in an advanced facility in Rockville, MD, to launch its
\nlife-saving cell therapy platforms in the US for critical cancer trials and
\nfuture commercial supply.<\/p>\n

Buy Now Full Report: https:\/\/www.novaoneadvisor.com\/report\/checkout\/9185<\/a>\n<\/p>\n

Report Scope of Cell & Gene Therapy
\nContract Research Organizations Market<\/p>\n

Report Coverage<\/p>\n

Details<\/p>\n

Market Size in 2025<\/p>\n

USD 5.88 Billion<\/p>\n

Market Size by 2034<\/p>\n

USD 13.76 Billion<\/p>\n

Growth Rate From 2025
\n to 2034<\/p>\n

CAGR of 9.91%<\/p>\n

Base Year<\/p>\n

2024<\/p>\n

Forecast Period<\/p>\n

2025-2034<\/p>\n

Segments Covered<\/p>\n

Type, Service,
\n Indication, Modality, Region<\/p>\n

Market Analysis
\n (Terms Used)<\/p>\n

Value (US$ Million\/Billion)
\n or (Volume\/Units)<\/p>\n

Regional scope<\/p>\n

North America;
\n Europe; Asia Pacific; Latin America; MEA<\/p>\n

Key Companies
\n Profiled<\/p>\n

Altasciences,
\n Allucent, ICON plc, Labcorp, Linical, Medpace, Thermo Fisher Scientific Inc.,
\n Precision Medicine Group, LLC., QPS Holdings, Syneos Health<\/p>\n

\u00a0<\/p>\n

Cell & Gene Therapy Contract
\nResearch Organizations Market Segmentation Analysis:<\/p>\n

By Type Analysis:<\/p>\n

The clinical
\nsegment<\/a> dominates in the cell and gene therapy contract research
\norganization market, as cell and gene therapy in clinical trials involves a stretch
\nof DNA<\/a>
\nto prevent or manage a genetic condition. It’s presently applied for treating
\nvarious types of blood cancers and a small number of rare genetic conditions.
\nThese trials lead to long-lasting or even one-time treatments, potentially
\navoiding the requirement for continuing medication.<\/p>\n

On the other hand, the preclinical segment
\nis expected to grow significantly during the forecast period, as CRO conducts
\npreclinical research and offer data to support drug or device development in
\nearly stages. It conducts preclinical research on behalf of biopharmaceutical
\nor life science organizations<\/a>. CROs are often applied for preclinical
\nstudies in fields like cell and gene therapy, immunology, and oncology. This
\nmodel removes the requirement for in-house lab space and personnel.<\/p>\n

By Service Analysis:<\/p>\n

The clinical monitoring segment dominated
\nthe market in 2024, as it ensures trial success with person-centric
\nspecialists, custom site funding, and operative excellence in all phases.
\nMonitoring in clinical trials supports study sponsors to assess and prove study
\ndata, improve patient safety, and ensure protocol agreement, in real-time and
\nfrom a centralized location, and with significantly lower requirements for
\nin-person site monitoring visits.<\/p>\n

On the other hand, the regulatory strategy
\nsegment is expected to grow at the fastest CAGR in the market during the
\nforecast period, as an efficient regulatory strategy is a game changer for
\norganizations, improving potential revenue, lowering product failure rates, and
\nbringing much-needed therapies to patients. A clear regulatory strategy includes
\nquickening timelines, cost incentives, and the chance to partner with the
\ngovernment to ensure a smooth advancement programme. <\/p>\n

By Therapeutic Area Analysis:<\/p>\n

The oncology<\/a>
\nsegment dominated the market in 2024, as cancer is the most common disease in gene
\ntherapy<\/a> clinical
\ntrials<\/a>. Cancer
\ngene therapy<\/a> mainly focuses on removing the cancer cells, blocking
\ntumor vascularization, and improving the immune response to cancer antigens.
\nMany gene and cell therapy strategies are being discovered for the treatment of
\na diversity of acquired diseases.<\/p>\n

On the other hand, the CNS disorders
\nsegment is expected to grow at the fastest CAGR in the market during the
\nforecast period, as gene therapy is significant for central nervous system
\n(CNS) disorders, opening up a compelling possible for the development of
\nadvanced therapies. It provides the potential of transformative and
\ndisease-modulating management opportunities.<\/p>\n

By Modality Analysis:<\/p>\n

The cell-based therapies segment dominated
\nthe market in 2024, as cell-based therapy, particularly stem cells, offers a
\nnew hope for patients suffering from irredeemable diseases, where treatment
\nstrategies focus on the treatment of the disease rather than treating it.\u00a0 It
\nis a significant branch of regenerative medicine with the ultimate aim of
\nimproving the body’s repair machinery through modulation, stimulation, and
\nregulation of the endogenous stem cell population and replenishing the cell
\npool toward tissue regeneration and homeostasis.<\/p>\n

\"A<\/p>\n

On the other hand, the gene therapies
\nsegment is expected to grow at the fastest CAGR in the market during the
\nforecast period, as gene therapies are applied to avoid, manage, or cure some
\ninherited disorders, like cystic fibrosis, alpha-1 antitrypsin deficiency, beta
\nthalassemia, haemophilia, and sickle cell disease. They may also be used to
\nmanage and treat cancers or infections, including HIV. Gene therapy has huge
\npotential to get rid of a patient\u2019s symptoms for life. Gene
\ntherapy<\/a> provides many people with an improved quality of life.<\/p>\n

By Regional Insights<\/p>\n

North America dominated the cell and gene
\ntherapy contract research organization market in 2024, due to it has strong
\nresearch ecosystem as well as federal funds that have supported academic
\nresearch, which in turn, has boosted private advancement, increasing
\ndiscoveries in technology, medicine, and advanced cell and gene therapies,
\nwhich drives the growth of the market. Growing investments in health research
\nand development (R&D), supported by private funding and government grants,
\nalso contribute to the growth of the market.<\/p>\n

\"A<\/p>\n

\u2b25\ufe0e For Instance, In October 2024, Minaris
\nRegenerative Medicine, LLC and TFBS Bioscience Inc. are pleased to announce a
\nstrategic partnership in cell and gene therapy (CGT), mainly in North America.
\nThis collaboration is designed to improve their abilities to drive industry
\ninnovation by providing one-stop-shop solutions.<\/p>\n

There were 4,321 contract research
\norganizations in the U.S. businesses as of 2024, a rise of 2.1% from 2023,
\nwhich adopt new technology of cell and gene therapies.\u00a0 U.S. leadership in
\nnovel drugs and medical devices is gaining regulatory approval. The country
\nalso ranks at the top in scientific Nobel prizes per capita, scientific impact
\nin academia, and research and development expenses per capita, which drive the
\ngrowth of the market.<\/p>\n

Why Asia Pacific is the Fastest Growing
\nin the Cell & Gene Therapy Contract Research Organizations Market?<\/p>\n

Strong presence of leading CROs in Asia
\nPacific, such as Novotech, Charles River Laboratories, Labcorp (Covance),
\nMedpace, and Caidya, drives the growth of the market. Increasing government
\nsupport for rare diseases research and gene therapy approvals, increasing
\noutsourcing, and revolution, which contribute to the growth of the market.<\/p>\n

Cell & Gene Therapy Contract
\nResearch Organizations Market Companies:<\/p>\n

\u2022 Altasciences<\/a><\/p>\n

\u2022 Allucent<\/a><\/p>\n

\u2022 ICON plc<\/p>\n

\u2022 Labcorp<\/a><\/p>\n

\u2022 Linical<\/p>\n

\u2022 Medpace<\/p>\n

\u2022 Thermo Fisher Scientific
\nInc.<\/a><\/p>\n

\u2022 Precision Medicine Group, LLC.<\/p>\n

\u2022 QPS Holdings<\/p>\n

\u2022 Syneos
\nHealth<\/a><\/p>\n

What is Going Around the Globe?<\/p>\n

\u2b25\ufe0e In April 2025, AGC
\nBiologics<\/a> Launched a New Dedicated Cell and Gene Business Division. The
\nnew Cell and Gene Technologies Division will focus on elevating existing AGC
\nBiologics capabilities and supporting developers in need of capacity,
\nscientific capabilities, and technically qualified cell and gene CDMO operators<\/p>\n

\u2b25\ufe0e In June 2024, Cryoport, Inc<\/a>., a global leader in
\nsupply chain solutions for the life sciences, and Minaris Regenerative Medicine
\nCo., Ltd., a global contract development and manufacturing organization for
\ncell and gene therapies, announced a collaborative partnership to offer fully
\nintegrated logistics and manufacturing solution to biotechnology and
\npharmaceutical companies for regenerative medicine products to helps the
\nadvancement of cell and gene therapies.<\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact at\u00a0sales@novaoneadvisor.com<\/a> \u00a0|
\n+1 804 441 9344<\/p>\n

Related Report<\/p>\n

\u2b25\ufe0e U.S. DNA Manufacturing Market – https:\/\/www.novaoneadvisor.com\/report\/us-dna-manufacturing-market<\/a>\n<\/p>\n

\u2b25\ufe0e Cell Culture Market – https:\/\/www.novaoneadvisor.com\/report\/cell-culture-market<\/a>\n<\/p>\n

\u2b25\ufe0e Cell & Gene Therapy Bioanalytical Testing Services Market – https:\/\/www.novaoneadvisor.com\/report\/cell-gene-therapy-bioanalytical-testing-services-market<\/a>\n<\/p>\n

\u2b25\ufe0e U.S. Plasmid DNA Contract Manufacturing Market – https:\/\/www.novaoneadvisor.com\/report\/plasmid-dna-contract-manufacturing-market<\/a>\n<\/p>\n

\u2b25\ufe0e Clinical Trials Market – https:\/\/www.novaoneadvisor.com\/report\/clinical-trials-market<\/a>\n<\/p>\n

Segments Covered in the Report<\/p>\n

This report forecasts revenue growth at
\ncountry levels and provides an analysis of the latest industry trends in each
\nof the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
\nhas segmented the cell & gene therapy contract research organizations market.<\/p>\n

By Type<\/p>\n

\u2022 Drug Discovery<\/p>\n

o\u00a0\u00a0
\nTarget Validation<\/p>\n

o\u00a0\u00a0
\nLead Identification<\/p>\n

o\u00a0\u00a0
\nLead Optimization<\/p>\n

\u2022 Preclinical<\/p>\n

\u2022 Clinical<\/p>\n

o\u00a0\u00a0
\nPhase I<\/p>\n

o\u00a0\u00a0
\nPhase II<\/p>\n

o\u00a0\u00a0
\nPhase III<\/p>\n

o\u00a0\u00a0
\nPhase IV<\/p>\n

By Service<\/p>\n

\u2022 Project & Clinical Trial Management<\/p>\n

\u2022 Regulatory Strategy<\/p>\n

\u2022 Data Management & Medical Writing<\/p>\n

\u2022 Clinical Monitoring<\/p>\n

\u2022 Quality Management \/ GMP Compliance<\/p>\n

\u2022 Biostatistics & Safety Monitoring<\/p>\n

\u2022 Patient & Site Recruitment<\/p>\n

\u2022 Technology Transfer<\/p>\n

\u2022 Others<\/p>\n

By Indication<\/p>\n

\u2022 Oncology<\/p>\n

\u2022 CNS Disorders<\/p>\n

\u2022 Infectious Diseases<\/p>\n

\u2022 Immunological Disorders<\/p>\n

\u2022 Cardiovascular Diseases<\/p>\n

\u2022 Respiratory Diseases<\/p>\n

\u2022 Diabetes<\/p>\n

\u2022 Ophthalmology<\/p>\n

\u2022 Pain Management<\/p>\n

\u2022 Others<\/p>\n

By Modality<\/p>\n

\u2022 Cell-Based Therapies<\/p>\n

\u2022 Gene Therapies<\/p>\n

\u2022 Gene-Modified Cell Therapies<\/p>\n

By Regional<\/p>\n

\u2022 North America<\/p>\n

\u2022 Europe<\/p>\n

\u2022 Asia Pacific<\/p>\n

\u2022 Latin America<\/p>\n

\u2022 Middle East and Africa (MEA)<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/9185<\/a>\n<\/p>\n

About-Us<\/p>\n

Nova One Advisor is a global leader
\nin market intelligence and strategic consulting, committed to delivering deep, data-driven
\ninsights that power innovation and transformation across industries. With a
\nsharp focus on the evolving landscape of life sciences, we specialize in
\nnavigating the complexities of cell and gene therapy, drug development, and the
\noncology market, enabling our clients to lead in some of the most revolutionary
\nand high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire
\nbiotech and pharmaceutical value chain, empowering startups, global
\nenterprises, investors, and research institutions that are pioneering the next
\ngeneration of therapies in regenerative medicine, oncology, and precision
\nmedicine. <\/p>\n

Web: https:\/\/www.novaoneadvisor.com\/<\/a><\/p>\n

Contact Us<\/p>\n

USA:\u00a0+1 804 420 9370<\/p>\n

Email: sales@novaoneadvisor.com<\/a><\/p>\n

For Latest Update
\nFollow Us: LinkedIn<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"According to Nova One Advisor, the global cell & gene therapy contract research organizations market size is calculated…\n","protected":false},"author":2,"featured_media":48491,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,79],"class_list":["post-48490","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/48490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=48490"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/48490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/48491"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=48490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=48490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=48490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}